IONS - Ionis Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
45.19
-1.16 (-2.50%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close46.35
Open46.41
Bid0.00 x 1100
Ask0.00 x 1200
Day's Range44.67 - 47.48
52 Week Range39.07 - 64.90
Volume836,717
Avg. Volume1,188,525
Market Cap6.203B
Beta (3Y Monthly)3.47
PE Ratio (TTM)N/A
EPS (TTM)-0.40
Earnings DateNov 5, 2018 - Nov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est56.42
Trade prices are not sourced from all markets
  • Biogen: Revenue Growth Is Expected in Q3
    Market Realist2 days ago

    Biogen: Revenue Growth Is Expected in Q3

    As we discussed in the previous part, analysts expect Biogen’s (BIIB) revenues to increase 8.3% to $3.33 billion during the third quarter. Biogen’s product portfolio includes multiple sclerosis products, spinal muscular atrophy products, biosimilars, and other products. Biogen’s portfolio also includes Anti-CD20 therapeutic programs.

  • Billionaire Tech Titans Award Millions to Make Scientists Stars
    Bloomberg5 days ago

    Billionaire Tech Titans Award Millions to Make Scientists Stars

    The no-strings-attached $3 million purse is more than double the amount of the Nobel Prize, and will go to two pairs and four individuals, totaling $18 million in prize money. C. Frank Bennett of Ionis Pharmaceuticals Inc. and Cold Spring Harbor Laboratory’s Adrian Krainer were awarded one of four life sciences prizes.

  • Billionaire Tech Titans Award Millions to Make Scientists Stars
    Bloomberg5 days ago

    Billionaire Tech Titans Award Millions to Make Scientists Stars

    The no-strings-attached $3 million purse is more than double the amount of the Nobel Prize, and will go to two pairs and four individuals, totaling $18 million in prize money. C. Frank Bennett of Ionis Pharmaceuticals Inc. and Cold Spring Harbor Laboratory’s Adrian Krainer were awarded one of four life sciences prizes.

  • GlobeNewswire5 days ago

    Factors of Influence in 2018, Key Indicators and Opportunity within Gogo, Jagged Peak Energy, Everbridge, Roku, Corium International, and Ionis Pharmaceuticals — New Research Emphasizes Economic Growth

    NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.
    Markit11 days ago

    See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.

    Short interest is moderate for IONS with between 5 and 10% of shares outstanding currently on loan. The net inflows of $2.94 billion over the last one-month into ETFs that hold IONS are not among the highest of the last year and have been slowing.

  • Here's Why Ionis Pharmaceuticals Rose 12.9% in September
    Motley Fool11 days ago

    Here's Why Ionis Pharmaceuticals Rose 12.9% in September

    The stock recovered from a surprising rejection at the end of August, but has tumbled once again in the first half of October.

  • The Wall Street Journal12 days ago

    [$$] Ionis, Roche Reach New Collaboration Agreement

    AG in a deal that could be worth up to $760 million for Ionis. As part of the deal to develop a drug called IONIS-FB-L(Rx) for the treatment of a wide range of diseases, Ionis will get a $75 million upfront payment and will then be eligible to receive up to $684 million in development, regulatory and sales milestone payments and license fees. Ionis is responsible for conducting a Phase 2 study, slated to begin in early 2019, in patients suffering from age-related macular degeneration -- the leading cause of blindness in the U.S. and developed countries -- and exploring the drug in a rare severe renal indication.

  • MarketWatch12 days ago

    Ionis's stock surges after Roche collaboration, which could be worth up to $759 million

    Shares of Ionis Pharmaceuticals Inc. rallied 4.7% in premarket trade, after the drug discovery company announced a new collaboration deal with Switzerland-based Roche Holding AG , which could be worth up to $759 million for Ionis. As part of the deal to develop IONIS-FB-L (Rx) for the treatment of complement-mediated diseases, Ionis will receive a $75 million upfront payment, and will be eligible for up to $684 million in milestone payments and license fees. Ionis is responsible for conducting a phase 2 trial of IONIS-FB-L for treating dry age-related macular degeneration (AMD) and for exploring the drug in a rare severe renal indication. Roche has the option to license the drug after the studies are completed. Ionis shares have shed 10.8% year to date through Tuesday, while the S&P 500 has gained 7.7%.

  • PR Newswire12 days ago

    Ionis Enters New Collaboration with Partner to Develop IONIS-FB-L Rx for Complement-Mediated Diseases

    CARLSBAD, Calif., Oct. 10, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS) today announced a new collaboration with Roche to develop IONIS-FB-LRx for the treatment of complement-mediated diseases. This collaboration will leverage Ionis' leadership in RNA-targeted therapeutics to develop IONIS-FB-LRx targeting Factor B (FB) for a broad range of diseases. The first indication the two companies will pursue is the treatment of patients with Geographic Atrophy (GA), the advanced stage of dry age-related macular degeneration (AMD).

  • A Financial Overview of Ionis Pharmaceuticals in October
    Market Realist13 days ago

    A Financial Overview of Ionis Pharmaceuticals in October

    Ionis Pharmaceuticals generated second-quarter revenues of $118.0 million compared to $122.3 million in the second quarter of 2017, which reflected ~15.0% YoY (year-over-year) growth. In the first half, Ionis Pharmaceuticals reported revenues of $262.2 million, compared to $228.1 million in the first half of 2017.

  • Ionis Pharmaceuticals: Recent Developments and Analysts’ Ratings
    Market Realist13 days ago

    Ionis Pharmaceuticals: Recent Developments and Analysts’ Ratings

    On October 4, Ionis Pharmaceuticals (IONS) stock closed at $47.48, which is an ~1.06% decline from its closing price of $51.58 on October 3. Ionis Pharmaceuticals’ October 4 closing stock price was ~38.0% below its 52-week high of $65.51. This reflects an 11.0% increase in September. Ionis Pharmaceuticals stock hit its 52-week low of $39.07 on May 8.

  • GlobeNewswire14 days ago

    Akcea Announces Changes to Board of Directors

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc. today announced that Damien McDevitt, Ph.D. Chief Business Officer of Ionis Pharmaceuticals, is joining the Akcea Board of Directors to replace Ionis Founder, Chairman and CEO Stanley T. Crooke, M.D., Ph.D. who has resigned from Akcea’s Board of Directors.

  • Cambridge's Akcea rebounds with FDA approval of first drug
    American City Business Journals16 days ago

    Cambridge's Akcea rebounds with FDA approval of first drug

    After having one of its drugs rejected by the FDA in August, Cambridge biotech Akcea Therapeutics Inc. turned the tide on Friday, receiving approval for another treatment for a rare genetic disease. The FDA approved Tegsedi, known generically as inotersen, an RNA-based drug that is designed to treat a rare and often fatal genetic disease called hereditary ATTR amyloidosis, or hATTR amyloidosis. According to Akcea (Nasdaq: AKCA), the drug works by slowing down production of a protein that can build up and impede nervous system and organ functions.

  • Reuters16 days ago

    Akcea Therapeutics genetic disease treatment gets FDA approval

    Akcea Therapeutics Inc said on Friday its treatment, developed along with Ionis Pharmaceuticals , which targets a rare genetic disease was approved by the U.S. Food and Drug Administration. Akcea's once-weekly injection, Tegsedi, treats hereditary ATTR amyloidosis patients with polyneuropathy. Polyneuropathy, a symptom of the disease, is the simultaneous malfunction of peripheral nerves in the body resulting in tingling, numbness and kidney dysfunction.

  • GlobeNewswire16 days ago

    Akcea Announces Its Access and Distribution Strategy for TEGSEDI™ (inotersen)

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc.(IONS), announced today that they are working together with Accredo® specialty pharmacy, a subsidiary of Express Scripts (ESRX), to distribute TEGSEDI™ (inotersen) subcutaneous injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. Approved by the U.S. Food and Drug Administration (FDA) today, TEGSEDI is the first and only subcutaneous RNA-targeting therapeutic offering patients an effective treatment for the polyneuropathy of hATTR amyloidosis.

  • GlobeNewswire16 days ago

    Akcea and Ionis Receive FDA Approval of TEGSEDI™ (inotersen) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), announced today that the U.S. Food and Drug Administration (FDA) has approved TEGSEDITM (inotersen) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. TEGSEDI is now approved in the U.S., European Union and Canada. “TEGSEDI is the first and only RNA-targeting therapeutic that powerfully reduces the production of TTR protein through a once-weekly subcutaneous injection offering patients an effective treatment for people living with polyneuropathy caused by hATTR amyloidosis.

  • Ionis Pharmaceuticals’ Revenue Stream
    Market Realist18 days ago

    Ionis Pharmaceuticals’ Revenue Stream

    Ionis Pharmaceuticals’ (IONS) revenue stream is segregated into two segments: Research and Development revenues from the collaborative agreements with other companies, and Commercial Revenues. Commercial Revenues include licensing and royalty revenues and Spinraza royalties. The chart below compares the revenues for Ionis Pharmaceuticals since the first quarter of 2017.

  • Ionis Pharmaceuticals’ Revenue Growth Rate
    Market Realist19 days ago

    Ionis Pharmaceuticals’ Revenue Growth Rate

    Ionis Pharmaceuticals (IONS), a leading biopharmaceutical company, has developed a variety of drugs for the treatment of life-threatening diseases through its broadly applicable drug discovery platform. Ionis reported earnings per share of -$0.29 on revenues of $117.7 million during the second quarter, reporting year-over-year growth of 5.0% during the quarter. The chart below compares the company’s revenues since the first quarter of 2017.

  • Ionis Pharmaceuticals’ Valuations on September 28
    Market Realist19 days ago

    Ionis Pharmaceuticals’ Valuations on September 28

    Ionis Pharmaceuticals (IONS) develops drugs for life-threatening diseases, and it commercializes the approved products in collaboration with other pharmaceutical companies. Ionis reported revenues of $118.0 million during the second quarter for 5.0% growth in YoY (year-over-year) revenues compared to the second quarter of 2017.

  • Simply Wall St.25 days ago

    When Will Ionis Pharmaceuticals Inc (NASDAQ:IONS) Become Profitable?

    Ionis Pharmaceuticals Inc’s (NASDAQ:IONS): Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics. With the latest financial year loss of -US$6.0m and a trailing-twelve month of -US$50.4m, the US$7.07b market-cap amplifies Read More...

  • See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.
    Markit25 days ago

    See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.

    Ionis Pharmaceuticals Inc NASDAQ/NGS:IONS

  • PR Newswire27 days ago

    Ionis Announces the Appointment of Two New Board Members

    CARLSBAD, Calif. , Sept. 24, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced the appointment of two new members to its Board of Directors ...

  • What Sarepta Therapeutics’ Valuation Trend Indicates
    Market Realistlast month

    What Sarepta Therapeutics’ Valuation Trend Indicates

    Sarepta Therapeutics (SRPT) incurred a net loss of $109.27 million in the second quarter of 2018 compared to a net loss of $63.05 million in Q2 2017. Its net loss per share was $1.15 in the second quarter of 2017. Despite the surge in revenues, Sarepta’s net loss widened due to higher operating expenses, which increased from $98.35 million in the second quarter of 2017 to $176.96 million in the second quarter of 2018.

  • See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.

    Ionis Pharmaceuticals Inc NASDAQ/NGS:IONS

  • A Look at Spectrum’s Financial Position in September
    Market Realistlast month

    A Look at Spectrum’s Financial Position in September

    In the second quarter, Spectrum Pharmaceuticals (SPPI) generated net revenues of $24.2 million compared to $34.3 million in Q2 2017. In the first half of the year, Spectrum Pharmaceuticals reported net revenues of $54.7 million compared to $63.4 million in H1 2017.